explore -WSS

explore

author：Wikipedia 2025-09-27 21:27:30 - browse：546

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Doctor appointment wait times are getting worse

WSS

Why the Crimean Bridge is key to Russia's war in Ukraine

The kidney, in all its complexity, is captured in a new atlas

Option Care buys Amedisys in $3.6 billion home care deal

States increasingly look to regulate hospital facility fees

Listen: Biogen's messy board & Laronde's data problem

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

knowledge

explore

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

TikTok cracks down on users posting about weight loss drugs

Heart attack and stroke risk calculators need revising

Option Care buys Amedisys in $3.6 billion home care deal

The high cost of giving birth even with insurance

PhRMA sues HHS over Medicare drug price negotiation

In Memoriam: Notable people who died in 2023

Lindsay Lohan welcomes 1st child with husband Bader Shammas

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ebola public health emergency is over, WHO declares

hotspot

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

RaDonda Vaught case: a double standard for nurses, physicians

Can food be medicine? And other questions about a new push

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Can food be medicine? And other questions about a new push

TikTok cracks down on users posting about weight loss drugs

leisure time

entertainment

focus

explore